X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Opdivo (nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor. It is being evaluated in combination with Cabometyx (cabozantinib) for the treatment of first-line advanced renal cell carcinoma.
Lead Product(s): Nivolumab,Cabozantinib
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
The companies will enter into a clinical trial collaboration evaluating XL092 (zanzalintinib), a tyrosine kinase inhibitor, in combination with AB521 in patients with advanced solid tumors including clear cell renal cell carcinoma.
Lead Product(s): Encoberminogene Rezmadenovec,AB521
Therapeutic Area: Oncology Product Name: XL092
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arcus Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 04, 2023
Details:
XL092 (Zanzalintinib) is a Vegf/metaxl/mer Inhibitor small molecule drug candidate, which is currently being evaluated in combination with "Pembrolizumab" for the treatment of PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck.
Lead Product(s): Encoberminogene Rezmadenovec,Pembrolizumab
Therapeutic Area: Oncology Product Name: XL092
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
Under the agreement, Insilico granted Exelixis an exclusive, worldwide license to develop and commercialize ISM3091, a best-in-class small molecule inhibitor of USP1, as a synthetic lethal target in the context of BRCA-mutated tumors, and other USP1-targeting compounds.
Lead Product(s): ISM3091
Therapeutic Area: Oncology Product Name: ISM3091
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Insilico Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 12, 2023
Details:
Cabometyx (Cabozantinib) tablet is a Mmultiple Rreceptor tyrosine kinases inhibitor, which is investigated for the treatment of advanced pancreatic and extra-pancreatic neuroendocrine tumors.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
Cabometyx (Cabozantinib) tablet is a multiple receptor tyrosine kinases inhibitor, being investigated in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
The collaboration aims for the development of novel masked antibody-drug conjugate (ADC) candidates, including ADG126 leveraging Adagene’s proprietary SAFEbody precision masking technology.
Lead Product(s): ADG126,Toripalimab
Therapeutic Area: Oncology Product Name: ADG126
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Adagene Suzhou Limited
Deal Size: Undisclosed Upfront Cash: $12.1 million
Deal Type: Collaboration May 04, 2023
Details:
Cabometyx (cabozantinib) is a multiple receptor tyrosine kinases inhibitor. These receptors are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, maintenance of the tumor microenvironment, etc.
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
Details:
ADU-1805 is a monoclonal antibody which blocks SIRPα, a significant immune-suppressive component of the tumor microenvironment which leads in improved immune system’s ability to attack tumors.
Lead Product(s): ADU-1805
Therapeutic Area: Oncology Product Name: ADU-1805
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Sairopa
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. It is being investigated in combination with cabometyx (cabozantinib) for advanced renal cell carcinoma.
Lead Product(s): Nivolumab,Cabozantinib
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
